Not sure many takers, report is pretty pricey.
I did note this in the excerpt:
“Key Hyperhidrosis Therapies expected to launch in the market are BOTOX, BBI-4000 (Sofpironium bromide), THVD-102, Umeclidinium, AT-5214, and many others.
In May 2023, Botanix Pharmaceuticals announced that a study is being conducted to assess the safety and efficacy of 3 concentrations of BBI-4000 and vehicle (4 treatment arms), applied for the treatment of axillary hyperhidrosis.”
Is this information accurate, it mentions BOT still conducting studies on safety and efficacy of 3 concentrations?
It also mentions a number of other treatments? My only concern about SB has been the degree of competition. Any others have thoughts on this?
Not sure many takers, report is pretty pricey.I did note this in...
-
- There are more pages in this discussion • 4,334 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.010(2.63%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 37.5¢ | 35.0¢ | $2.813M | 7.727M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 199142 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 218640 | 8 |
View Market Depth
| Last trade - 14.35pm 15/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |